Correlation Between Moleculin Biotech and Cocrystal Pharma

Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Cocrystal Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Cocrystal Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Moleculin Biotech and Cocrystal Pharma, you can compare the effects of market volatilities on Moleculin Biotech and Cocrystal Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Cocrystal Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Cocrystal Pharma.

Diversification Opportunities for Moleculin Biotech and Cocrystal Pharma

0.5

Correlation Coefficient

Moleculin Biotech  Cocrystal Pharma

Very weak diversification

The 3 months correlation between Moleculin and Cocrystal is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Cocrystal Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cocrystal Pharma and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Cocrystal Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cocrystal Pharma has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Cocrystal Pharma go up and down completely randomly.

Pair Corralation between Moleculin Biotech and Cocrystal Pharma

Given the investment horizon of 90 days Moleculin Biotech is expected to generate 4.1 times more return on investment than Cocrystal Pharma. However, Moleculin Biotech is 4.1 times more volatile than Cocrystal Pharma. It trades about 0.04 of its potential returns per unit of risk. Cocrystal Pharma is currently generating about -0.14 per unit of risk. If you would invest  179.00  in Moleculin Biotech on December 30, 2024 and sell it today you would lose (75.00) from holding Moleculin Biotech or give up 41.9% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Moleculin Biotech  vs.  Cocrystal Pharma

Moleculin Biotech

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Moleculin Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Moleculin Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Cocrystal Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cocrystal Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Moleculin Biotech and Cocrystal Pharma

The main advantage of trading using opposite Moleculin Biotech and Cocrystal Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Cocrystal Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will offset losses from the drop in Cocrystal Pharma's long position.

The idea behind Moleculin Biotech and Cocrystal Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.